title: Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.
abstract: OBJECTIVE
  This study examined plaque psoriasis (PsO) patient characteristics across injectable biologics.
  
  
  METHODS
  Data were collected from 400 US dermatologists randomly selecting five charts each for patients with PsO (patient n  =  2000): adalimumab (ADA; n  =  447), etanercept (ETA; 539), ustekinumab (UST) 45 mg (511) and UST 90 mg (503). Physicians had to have been in practice 2-30 years, managing 10+  patients (5 + with biologics for PsO). Generalized estimating equation models, weighted according to inverse probability of patient selection and accounting for patient correlation within physicians, examined patient measures as a function of treatment (UST 90 mg = reference).
  
  
  RESULTS
  Patients on UST 90 mg had higher odds of weighing  >100 kg (adjusted mean  =  34.4%) vs. ADA (10.9%), ETA (5.5%) or UST 45 mg (6.8%), greater body surface affected and higher odds of severe PsO prior to treatment and higher odds of prior biologics use. Mean prior biologics used was higher with UST 90 mg versus ADA or ETA. Number of comorbidities was higher with UST 90 mg versus ETA or UST 45 mg.
  
  
  CONCLUSIONS
  Among biologics-treated patients with PsO, UST 90 mg appears to be used in patients with greater weight, baseline severity and prior biologics experience than ADA, ETA or UST 45 mg. UST 90 mg is used in patients with more comorbidities than other treatments except ADA.
authors.affiliation: a Janssen Scientific Affairs, LLC , Horsham , PA , USA .
authors.forename: Mingliang
authors.initials: M
authors.lastname: Zhang
authors.affiliation: b Kantar Health , New York , NY , USA , and.
authors.forename: Amir
authors.initials: A
authors.lastname: Goren
authors.affiliation: a Janssen Scientific Affairs, LLC , Horsham , PA , USA .
authors.forename: Seina
authors.initials: S
authors.lastname: Lee
authors.affiliation: b Kantar Health , New York , NY , USA , and.
authors.forename: Marco D
authors.initials: MD
authors.lastname: DiBonaventura
authors.affiliation: c Janssen Scientific Affairs, LLC , Titusville , NJ , USA.
authors.forename: William H
authors.initials: WH
authors.lastname: Olson
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D000328:Adult; D001688:Biological Products / Q000627:therapeutic use; D000068800:Etanercept / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D012189:Retrospective Studies; D000069549:Ustekinumab / Q000627:therapeutic use*
chemical_list: D001688:Biological Products; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept
keywords: Psoriasis; adalimumab; biologics; etanercept; ustekinumab